Form 4: Guardant Health CIO's Routine Stock Transactions

Guardant Health's Chief Information Officer, Kumud Kalia, reported the vesting of restricted stock units and a subsequent tax-related sale of company stock.

Summary

• Kumud Kalia, Chief Information Officer of Guardant Health, Inc. (GH), reported transactions involving company common stock and restricted stock units (RSUs).
• On December 15, 2025, 637 shares of common stock were acquired through the vesting of restricted stock units.
• Concurrently, 323 shares of common stock were disposed of at a price of $102.67 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Kumud Kalia beneficially owns 22,679 shares of common stock directly.
• The RSU award was granted on June 9, 2023, vesting over a three-year period, with 33% vesting on June 15, 2024, and the remaining 67% vesting in equal quarterly installments over the subsequent two years.
• After the reported transactions, 1,275 derivative securities (Restricted Stock Units) are beneficially owned directly.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation (RSU vesting and tax-related sales). These are expected events and do not inherently indicate positive or negative sentiment regarding the company's performance or outlook.

Positives

• The vesting of 637 restricted stock units indicates the fulfillment of executive compensation agreements, reflecting continued alignment of management interests with shareholder value over time.

Negatives

• A sale of 323 shares of common stock occurred, although this was specifically to cover tax withholding obligations related to the RSU vesting, which is a common and expected practice.

Future Outlook

The filing indicates that the remaining 67% of the restricted stock unit award will vest in equal quarterly installments over a two-year period following June 15, 2024.

Industry Context

This filing details a routine insider transaction related to executive compensation, which is a standard practice across all industries for publicly traded companies. It does not provide broader industry trends or competitive insights.

Comparison to Industry Standards

• The vesting of restricted stock units and subsequent sale of shares for tax withholding is a standard and widely accepted practice for executive compensation in publicly traded companies across various sectors, including the healthcare technology industry where Guardant Health operates.
• The structure of the RSU award, with a multi-year vesting schedule, aligns with common industry practices designed to retain key executives and align their long-term interests with shareholder value.

Stakeholder Impact

• Shareholders: Minimal direct impact, as these are routine compensation-related transactions and do not reflect a discretionary sale or purchase based on new material information.
• Employees: Reflects standard executive compensation practices, which can be a factor in talent attraction and retention.

Next Steps

• The remaining 67% of the restricted stock unit award will continue to vest in equal quarterly installments over the two-year period following June 15, 2024.

Key Dates

Keywords

Guardant Health, GH, Insider Transaction, Form 4, Restricted Stock Units, RSU, Stock Vesting, Executive Compensation, Tax Withholding, Kumud Kalia